Outcomes of COVID-19 among Patients with End Stage Renal Disease on Remdesivir

Vijairam Selvaraj, Muhammad Baig, Kwame Dapaah-Afriyie, Arkadiy Finn, Atin Jindal, George Bayliss
doi: https://doi.org/10.1101/2021.02.10.21251527

Article Information

doi 
https://doi.org/10.1101/2021.02.10.21251527
History 
  • February 12, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Vijairam Selvaraj1,2,*,
  2. Muhammad Baig1,2,
  3. Kwame Dapaah-Afriyie1,2,
  4. Arkadiy Finn1,2,
  5. Atin Jindal1,2 and
  6. George Bayliss2,3
  1. 1Division of Hospital Medicine, The Miriam Hospital, Providence, Rhode Island
  2. 2Warren Alpert Medical School of Brown University, Providence, Rhode Island
  3. 3Division of Kidney Disease and Hypertension, Rhode Island Hospital, Providence, Rhode Island
  1. ↵*Address for Correspondence
    Vijairam Selvaraj MD, MPH, FACP, The Miriam Hospital, Warren Alpert Medical School of Brown University, 164 Summit Ave, Providence, RI, 02906, Email: vijairam.selvaraj{at}lifespan.org, Ph: 413-271-0421
Back to top
Posted February 12, 2021.
Download PDF
Data/Code
Email
Outcomes of COVID-19 among Patients with End Stage Renal Disease on Remdesivir
Vijairam Selvaraj, Muhammad Baig, Kwame Dapaah-Afriyie, Arkadiy Finn, Atin Jindal, George Bayliss
medRxiv 2021.02.10.21251527; doi: https://doi.org/10.1101/2021.02.10.21251527
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area